S&P 500
(0.39%) 5 327.59 points
Dow Jones
(-0.28%) 39 559 points
Nasdaq
(0.85%) 16 944 points
Oil
(1.33%) $78.60
Gas
(1.83%) $2.89
Gold
(-1.05%) $2 367.70
Silver
(-1.45%) $31.04
Platinum
(0.10%) $1 050.80
USD/EUR
(-0.29%) $0.921
USD/NOK
(-0.85%) $10.61
USD/GBP
(-0.14%) $0.785
USD/RUB
(-0.85%) $89.43

Realtime updates for Aileron Therapeutics Inc [ALRN]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Last Updated23 May 2024 @ 09:41

-0.27% $ 3.68

Live Chart Being Loaded With Signals

Commentary (23 May 2024 @ 09:41):

Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial...

Stats
Today's Volume 1 372.00
Average Volume 92 575.00
Market Cap 79.45M
EPS $0 ( 2024-05-13 )
Next earnings date ( $-0.160 ) 2024-08-09
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -1.160
ATR14 $0.0260 (0.70%)
Insider Trading
Date Person Action Amount type
2024-05-16 Cunningham Timothy M. Buy 0
2024-05-01 University Of Texas/texas Am Investment Management Co Sell 3 100 Common Stock
2024-05-01 University Of Texas/texas Am Investment Management Co Sell 100 Common Stock
2024-05-01 University Of Texas/texas Am Investment Management Co Sell 1 750 Common Stock
2024-05-01 University Of Texas/texas Am Investment Management Co Sell 380 Common Stock
INSIDER POWER
-86.90
Last 98 transactions
Buy: 18 805 101 | Sell: 819 636

Aileron Therapeutics Inc Correlation

10 Most Positive Correlations
FAST0.849
KNSL0.844
WIX0.84
FATE0.838
HMST0.816
KROS0.815
CDNS0.808
LQDA0.805
NOTV0.805
NICE0.804
10 Most Negative Correlations
AY-0.836
PLXS-0.811
NEON-0.81
KTRA-0.802

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Aileron Therapeutics Inc Financials

Annual 2023
Revenue: $0
Gross Profit: $-119 000 (0.00 %)
EPS: $-3.42
FY 2023
Revenue: $0
Gross Profit: $-119 000 (0.00 %)
EPS: $-3.42
FY 2022
Revenue: $0
Gross Profit: $-169 000 (0.00 %)
EPS: $-5.95
FY 2021
Revenue: $0.00
Gross Profit: $0.00 (0.00 %)
EPS: $-13.31

Financial Reports:

No articles found.

Aileron Therapeutics Inc Options Data

Calls

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

Puts

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

Aileron Therapeutics Inc

Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators